Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event‐free survival in intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event‐free survival in intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Published:2021-07-10 Issue:11 Volume:68 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Pinto Navin¹²^ORCID,Navarro Sandi L.³,Rimorin Christine³,Wurscher Michelle³,Hawkins Douglas S.¹²^ORCID,McCune Jeannine S.⁴

Affiliation:

1. Seattle Children's Hospital Seattle Washington USA

2. Department of Pediatrics University of Washington Seattle Washington USA

3. Division of Public Health Sciences Fred Hutchinson Cancer Research Center Seattle Washington USA

4. Department of Hematologic Malignances Translational Sciences City of Hope Duarte California USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29203

Reference64 articles.

1. Rhabdomyosarcoma

2. Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

3. In vitro purging of human rhabdomyosarcoma cells using 4‐hydroperoxycyclophosphamide;Ozkaynak MF;Cancer Res,1990

4. Drug Focus: Pharmacogenetic studies related to cyclophosphamide-based therapy

5. Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer;Cancer Chemotherapy and Pharmacology;2024-07-30

2. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics;Advances in Pharmacological and Pharmaceutical Sciences;2024-01

3. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma;Scientific Reports;2023-07-21

4. Children's Oncology Group's 2023 blueprint for research: Pharmacy;Pediatric Blood & Cancer;2023-07-17

5. Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide;Clinical and Translational Science;2022-09-24